Functional characterization of the 9q34.13 locus identifies RAPGEF1 as modulating risk for melanoma and nevi via RAS activation.

Thakur, R.; Xu, M.; Thornock, AM.; Yon, J.; Anyaso-Samuel, S.; Lauss, M.; Rehling, T.; Bui-Raborn, L.; Sowards, H.; Duncan, G.; Jessop, L.; Myers, T.; Chari, R.; Long, E.; Funderburk, K.; Yin, J.; Hennessey, R.; Hseih, E.; Levin, H.; Machiela, MJ.; Zhang, T.; Jonsson, G.; Bishop, DT.; Newton-Bishop, J.; Nsengimana, J.; Iles, MM.; Landi, MT.; Law, MH.; Andresson, T.; Choi, J.; Zon, LI.; Shi, J.; Brown, KM.

Functional characterization of the 9q34.13 locus identifies RAPGEF1 as modulating risk for melanoma and nevi via RAS activation.

All Authors

Thakur, R.

Xu, M.

Thornock, AM.

Yon, J.

Anyaso-Samuel, S.

Lauss, M.

Rehling, T.

Bui-Raborn, L.

Sowards, H.

Duncan, G.

Show 10 more

LTHT Author

Iles, Mark

LTHT Department

NIHR Leeds Biomedical Research Centre

Publication Date

2026

Item Type

Journal Article
Preprint

Abstract

Genome-wide association studies identified a melanoma- and nevus count-associated locus on chromosome band 9q34.13. Fine-mapping and melanocyte expression data collectively suggest two potential causal genes with opposite association with risk: higher levels of Rap guanine nucleotide exchange factor 1 (RAPGEF1) and lower levels of uridine-cytidine kinase 1 (UCK1). Colocalization analyses and conditional TWAS suggest multiple causal cis-regulatory sequence variants in partial linkage disequilibrium (LD) to each other. Melanocyte capture-HiC and CRISPR-inhibition demonstrated regulatory interactions between fine-mapped variants and the RAPGEF1 and UCK1 promoters. Focusing on RAPGEF1, we demonstrate RAPGEF1 expression promotes melanocyte growth and drives malignant transformation of human immortalized melanocytes. Following treatment with human EGF, RAPGEF1 overexpression activated both RAP1 and RAS. Further, we show RAPGEF1 expression is significantly enriched in melanomas lacking strongly activating RAS-MAPK mutations, suggesting that RAPGEF1 may promote oncogenic RAS-MAPK signaling in melanomas. Furthermore, in these tumors, we provide preliminary evidence to support the prognostic relevance of RAPGEF1 expression in patients lacking RAS or BRAF mutations. Together with other recent studies, these data suggest that germline variation influencing RAS activation may play a key role in nevus development and melanoma risk.